Background: Previous studies reported inconsistent effects of testosterone therapy on the lipid profile in men with hypogonadism.
Methods: Of 356 men with hypogonadism and T2DM, 178 received TU 1000 mg/12 weeks (T-group), 178 opted against treatment (CTRL). Changes over time between groups were compared and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the two groups.
Results: Mean follow-up 8.2±2.9, baseline age 61.5±5.4 (T-group) and 63.7±4.9 (CTRL) years. Total cholesterol (mmol/L) decreased by 2.9±0.1 (from 8.3±1.1 to 5.2±0.3) at 11 years in T-group and increased by 1.1±0.1 (from 7.1±1.2 to 8.1±1.3) in CTRL. Estimated adjusted difference between groups: -4.0 (p<0.0001 for all). HDL (mmol/L) increased by 0.5±0.0 (from 1.0±0.4 to 1.6±0.4) in T-group and decreased by 0.3±0.0 (from 1.1±0.5 to 0.9±0.5) in CTRL, difference between groups: 0.8 (p<0.0001 for all). LDL (mmol/L) decreased by 1.9±0.1 (from 4.7±0.9 to 2.6±0.2) in T-group and increased by 0.9±0.1 (from 4.1±1.4 to 4.9±1.5) in CTRL, difference between groups: -2.8 (p<0.0001 for all). Triglyceride (mmol/L) decreased by 1.1±0.0 (from 3.5±0.6 to 2.2±0.1) in T-group and increased by 0.5±0.0 (from 3.1±0.6 to 3.7±0.6) in CTRL, difference between groups: -1.7 (p<0.0001 for all). Non-HDL (mmol/L) decreased by 5.5±0.3 (from 9.6±4.3 to 3.4±0.8) in T-group and increased by 4.9±0.3 (from 8.0±3.9 to 11.3±6.8) in CTRL, difference between groups: -10.4 (p<0.0001 for all). Remnant cholesterol (mmol/L) decreased by 1.4±0.1 (from 2.6±1.0 to 1.0±0.2) in T-group and increased by 0.5±0.1 (from 2.0±1.0 to 2.3±0.7) in CTRL, difference between groups: -1.9 (p<0.0001 for all).
Conclusions: Long-term treatment with TU in men with hypogonadism and T2DM progressively improved the lipid profile, which worsened in controls.
F. Saad: Consultant; Self; Bayer AG. Stock/Shareholder; Self; AbbVie Inc., Bayer AG. K.S. Haider: None. A. Haider: None.
Bayer AG
